984 related articles for article (PubMed ID: 33764894)
1. High-dose ACEi might be harmful in COVID-19 patients with serious respiratory distress syndrome by leading to excessive bradykinin receptor activation.
Székács B; Várbíró S; Debreczeni L
Physiol Int; 2021 Mar; ():. PubMed ID: 33764894
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology.
Sohaei D; Hollenberg M; Janket SJ; Diamandis EP; Poda G; Prassas I
Crit Rev Clin Lab Sci; 2023 Jan; 60(1):25-40. PubMed ID: 35930434
[TBL] [Abstract][Full Text] [Related]
3. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
Meini S; Zanichelli A; Sbrojavacca R; Iuri F; Roberts AT; Suffritti C; Tascini C
Front Immunol; 2020; 11():2014. PubMed ID: 32849666
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D
Elife; 2020 Jul; 9():. PubMed ID: 32633718
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
7. Kinin B1 receptors as a therapeutic target for inflammation.
Qadri F; Bader M
Expert Opin Ther Targets; 2018 Jan; 22(1):31-44. PubMed ID: 29168929
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg
Sodhi CP; Wohlford-Lenane C; Yamaguchi Y; Prindle T; Fulton WB; Wang S; McCray PB; Chappell M; Hackam DJ; Jia H
Am J Physiol Lung Cell Mol Physiol; 2018 Jan; 314(1):L17-L31. PubMed ID: 28935640
[TBL] [Abstract][Full Text] [Related]
9. Does hereditary angioedema make COVID-19 worse?
Xu Y; Liu S; Zhang Y; Zhi Y
World Allergy Organ J; 2020 Sep; 13(9):100454. PubMed ID: 32834893
[TBL] [Abstract][Full Text] [Related]
10. The Renin-Angiotensin System in COVID-19: Can Long COVID Be Predicted?
König S; Vollenberg R; Tepasse PR
Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511837
[TBL] [Abstract][Full Text] [Related]
11. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
Tschöpe C; Schultheiss HP; Walther T
J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy.
Wilkinson-Berka JL; Fletcher EL
Curr Pharm Des; 2004; 10(27):3313-30. PubMed ID: 15544518
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and Lung Mast Cells: The Kallikrein-Kinin Activation Pathway.
Nagashima S; Dutra AA; Arantes MP; Zeni RC; Klein CK; de Oliveira FC; Piper GW; Brenny ID; Pereira MRC; Stocco RB; Martins APC; de Castro EM; Vaz de Paula CB; Amaral ANM; Machado-Souza C; Baena CP; Noronha L
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163636
[TBL] [Abstract][Full Text] [Related]
14. Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity.
Alfaro E; Díaz-García E; García-Tovar S; Zamarrón E; Mangas A; Galera R; Nanwani-Nanwani K; Pérez-de-Diego R; López-Collazo E; García-Río F; Cubillos-Zapata C
Front Immunol; 2022; 13():909342. PubMed ID: 35812405
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.
Sharma JN; Al-Sherif GJ
ScientificWorldJournal; 2006 Oct; 6():1247-61. PubMed ID: 17041716
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
Dendorfer A; Wolfrum S; Schäfer U; Stewart JM; Inamura N; Dominiak P
Hypertension; 2000 Jan; 35(1 Pt 1):32-7. PubMed ID: 10642271
[TBL] [Abstract][Full Text] [Related]
17. Potential Pathways and Pathophysiological Implications of Viral Infection-Driven Activation of Kallikrein-Kinin System (KKS).
Coelho SVA; Augusto FM; Arruda LB
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400022
[TBL] [Abstract][Full Text] [Related]
18. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
[TBL] [Abstract][Full Text] [Related]
19. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors.
Prado GN; Taylor L; Zhou X; Ricupero D; Mierke DF; Polgar P
J Cell Physiol; 2002 Dec; 193(3):275-86. PubMed ID: 12384980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
